Charles River Laboratories News and Resources

Charles River Laboratories has announced a contract development and manufacturing organisation (CDMO) collaboration with Axovia Therapeutics Ltd. The collaboration will see Charles River manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for

Charles River Laboratories International, Inc. and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, have announced a Good Manufacturing Practice (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement. Ship of Theseus is developing a proprietary

Charles River Laboratories, a provider of products and services to help expedite the discovery, early-stage development and safe manufacture of novel drugs and therapeutics, has announced a high-quality (HQ) plasmid DNA development and manufacturing agreement with the National University of

Charles River Laboratories, a cell therapy contract development and manufacturing organisation (CDMO), has announced a new partnership with Navega Therapeutics. The collaboration is centred on the production of an adeno-associated virus 9 (AAV9) candidate, NT-Z001, a non-opioid alternative for patients living